# Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS)

> **NCT01062490** · PHASE2 · COMPLETED · sponsor: **medac GmbH** · enrollment: 45 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Treosulfan

## Key facts

- **NCT ID:** NCT01062490
- **Lead sponsor:** medac GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2008-07
- **Final completion:** 2009-10
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2010-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01062490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01062490, "Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01062490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*